Buprenorphine Hydrochloride Injection, Solution
NDC Package 0409-2012-32
Package Information
Buprenorphine Hydrochloride injection is indicated for the management of pain severe enough to require an opioid analgesic and for which alternate treatments are inadequate. This formulation utilizes a injection, solution delivery system. Marketed by Hospira, Inc., this product is identified by NDC 0409-2012 and is authorized under FDA application ANDA074137.
Identification & Billing
- RxCUI: 1655032 - buprenorphine HCl 0.3 MG in 1 ML Cartridge
- RxCUI: 1655032 - 1 ML buprenorphine 0.3 MG/ML Cartridge
- RxCUI: 1655032 - buprenorphine 0.3 MG/ML (as buprenorphine HCl 0.324 MG/ML) per 1 ML Cartridge
Clinical Specifications
- Intramuscular - Administration within a muscle.
- Intravenous - Administration within or into a vein or veins.
Regulatory & Marketing
Hierarchy Structure
- 0409 - Hospira, Inc.
- 0409-2012 - Buprenorphine Hydrochloride
- 0409-2012-32 - 10 CARTRIDGE in 1 CARTON / 1 mL in 1 CARTRIDGE (0409-2012-03)
- 0409-2012 - Buprenorphine Hydrochloride
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Billing & HCPCS Mapping
To facilitate insurance claims and reimbursement, this drug package is mapped to specific HCPCS administrative codes. This crosswalk aligns clinical data with the billing standards used in ASP (Average Sales Price), AWP, and OPPS payment systems. Use the cards below to identify the correct billable units for provider claims.
Note for Medical Coders: These mappings are synthesized from various CMS datasets including OPPS, PrEP, and DAC (Data Analysis and Coding) contractors. Always confirm unit conversions against the current quarter's pricing files before final submission.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 0409-2012-32 identifies a specific commercial package of 10 cartridge in 1 carton / 1 ml in 1 cartridge (0409-2012-03) of Buprenorphine Hydrochloride, a human prescription drug labeled by Hospira, Inc.. This injection, solution is formulated for intramuscular; intravenous use and contains buprenorphine hydrochloride as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Hospira, Inc. on June 14, 2005. The current certification is valid through December 31, 2026.
How is this Hospira, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 00409201232. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Labeler segment to maintain the 5-4-2 structure.
